勃林格殷格翰新一代溶栓药物美通立®在华获批，用于治疗急性缺血性卒中

Core Viewpoint - Boehringer Ingelheim announced that the National Medical Products Administration of China has officially approved Metalyse® (generic name: Tenecteplase injection) for the treatment of acute ischemic stroke (AIS) within 4.5 hours of onset [1] Group 1 - The approval of Metalyse® marks a significant advancement in the treatment options available for acute ischemic stroke in China [1] - This development is expected to enhance patient outcomes by providing a timely therapeutic intervention [1]